Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Longfor Placement - Chairwoman/Co-Founder Selling in the Mix

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Longfor Properties / Equity Capital Markets

<p>Citi announced a placement to sell 78.39 million shares of Longfor after market close today. The deal was said to be a delta hedge to facilitate a collar and additional call option transaction with Junson Development International, which is held by family trust of Cai Kui, the ex-husband of Longfor chairwoman Wu Yajun. In this insight, we will look at the details of the deal and provide our views on the deal. </p>

Citi announced a placement to sell 78.39 million shares of Longfor after market close today. The deal was said to be a delta hedge to facilitate a collar and additional call option transaction with Junson Development International, which is held by family trust of Cai Kui, the ex-husband of Longfor chairwoman Wu Yajun. In this insight, we will look at the details of the deal and provide our views on the deal. 

Longfor Placement: A Perplexing Derivative Transaction of Major Shareholder